Fly News Breaks for August 2, 2019
Aug 2, 2019 | 07:38 EDT
Oppenheimer analyst Steven Lichtman raised his price target for Tandem Diabetes to $84 from $80 following the company's Q2 results, saying sales exceeded expectations significantly, with sales and adjusted EBITDA guidance both raised. In a research note to investors, Lichtman says looking forward, the key drivers in his focus are the launch of Control-IQ in Q4 a now building renewal cycle, international expansion and what he continues to believe is an under-appreciated t:sport opportunity.
News For TNDM From the Last 2 Days
Sep 18, 2019 | 18:46 EDT
UP AFTER EARNINGS: Herman Miller (MLHR) up 9.1%. ALSO HIGHER: Savara (SVRA) up 11.1% after announcing presentation of additional data for Molgradex at ERS... China Biologic (CBPO) up 7.6% after disclosing "going private" offer from Beachhead Holdings and Citic Capital... NCR Corp (NCR) up 3.4% after backing FY19 guidance, retiring convertible preferred stock... Microsoft (MSFT) up 1.3% after announcing new $40B buyback, raising dividend by 11%... Tandem Diabetes (TNDM) up 1.3% after disclosing t:slim X2 pump results. DOWN AFTER EARNINGS: U.S. Steel (X) down 8.7% after negative Q3 pre-announcement. ALSO LOWER: Provention Bio (PRVB) down 9.4% after equity offering... Plains All American (PAA) down 1.7% after secondary offerings... Costco (COST) down 0.8% after being cut to Underperform at Bernstein. Movers as of 18:30ET.
Sep 18, 2019 | 07:24 EDT
Meeting to be held in Boston on September 19 hosted by Oppenheimer.